Related Experiment Video
Updated: Oct 17, 2025
Isolation and Enrichment of Human Adipose-derived Stromal Cells for Enhanced Osteogenesis
Published on: January 12, 2015
Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling
Wei Bing Jing1, Hongjuan Ji2, Rui Jiang3
1Department of Orthopedics, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, 212300, Jiangsu Province, China.
Background:
Osteoporosis is a widespread chronic disease characterized by low bone density. There is currently no gold standard treatment for osteoporosis. The aim of this study was to explore the role and mechanism of Astragaloside on osteogenic differentiation of MC3T3-E1 cells.
Methods:
MC3T3-E1 cells were divided into control and different dose of Astragaloside (10, 20, 40, 50, and 60 μg/ml). Then, ALP and ARS staining were performed to identify the effects of Astragaloside for early and late osteogenic capacity of MC3T3-E1 cells, respectively. Real-time PCR and western blot were performed to assess the ALP, OCN, and OSX expression. PI3K/Akt signaling pathway molecules were then assessed by Western blot. Finally, PI3K inhibitor, LY294002, was implemented to assess the mechanism of Astragaloside in promoting osteogenic differentiation of MC3T3-E1 cells.
Results:
Astragaloside significantly increased the cell viability than the control group. Moreover, Astragaloside enhanced the ALP activity and calcium deposition than the control groups. Compared with the control group, Astragaloside increased the ALP, OCN, and OSX expression in a dose-response manner. Western blot assay further confirmed the real-time PCR results. Astragaloside could significantly increase the p-PI3K and p-Akt expression than the control group. LY294002 partially reversed the promotion effects of Astragaloside on osteogenic differentiation of MC3T3-E1 cells. LY294002 partially reversed the promotion effects of Astragaloside on ALP, OCN, and OSX of MC3T3-E1 cells.
Conclusion:
The present study suggested that Astragaloside promoted osteogenic differentiation of MC3T3-E1 cells through regulating PI3K/Akt signaling pathway.
Insights
Astragaloside promotes bone formation in cells by activating the PI3K/Akt pathway. This natural compound enhances osteogenic differentiation, offering potential for osteoporosis treatment.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoporosis is a prevalent condition marked by low bone density, lacking a definitive treatment.
- Investigating novel therapeutic agents for osteoporosis is crucial.
Purpose of the Study:
- To elucidate the role and mechanism of Astragaloside in promoting osteogenic differentiation of MC3T3-E1 cells.
- To explore Astragaloside's effects on bone cell development and the underlying signaling pathways.
Main Methods:
- MC3T3-E1 cells were treated with varying doses of Astragaloside.
- Alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining assessed osteogenic capacity.
- Real-time PCR and Western blot analyzed gene and protein expression, including PI3K/Akt pathway markers.
- A PI3K inhibitor (LY294002) was used to confirm the mechanism.
Main Results:
- Astragaloside significantly enhanced MC3T3-E1 cell viability, ALP activity, and calcium deposition.
- Dose-dependent increases in ALP, OCN, and OSX expression were observed with Astragaloside treatment.
- Astragaloside upregulated phosphorylated PI3K and Akt, indicating PI3K/Akt pathway activation.
- Inhibition of PI3K/Akt partially reversed Astragaloside's osteogenic effects.
Conclusions:
- Astragaloside promotes osteogenic differentiation in MC3T3-E1 cells.
- The PI3K/Akt signaling pathway is a key mechanism through which Astragaloside exerts its osteogenic effects.
- Astragaloside shows therapeutic potential for osteoporosis treatment.
Related Concept Videos
01:16TGF - β Signaling Pathway
01:22PI3K/mTOR/AKT Signaling Pathway